COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
Compounds targeting Axl and Mer kinases are developed to inhibit their signaling pathways, addressing cancer progression and metastasis by modulating their activity, providing a therapeutic solution for kinase-dependent disorders.
BR112020015201B1Active Publication Date: 2026-09-01EXELIXIS INC
0 Cites 0 Cited by
Patent Information
- Application Number
- BR112020015201
- Authority / Receiving Office
- BR · BR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-11-09
- Filing Date
- 2019-01-25
- Publication Date
- 2026-09-01
- Estimated Expiration
- 2039-01-25
AI Technical Summary
Technical Problem
There is a need for compounds that inhibit TAM receptor tyrosine kinases such as Axl and Mer to treat various cancers, as their overexpression leads to tumor growth and metastasis.
Method used
Development of compounds of specific formulas (I and A) that modulate the activity of Axl and Mer receptor tyrosine kinases, potentially inhibiting their signaling pathways to treat kinase-dependent disorders.
Benefits of technology
The compounds effectively target and inhibit Axl and Mer kinases, offering a therapeutic approach to manage cancer progression and metastasis by modulating their signaling pathways.
✦ Generated by Eureka AI based on patent content.
Abstract
These compounds of formula i inhibit, regulate, and / or modulate receptor kinase signal transduction pathways, particularly AXL and MER, with respect to changes in cellular activities, as mentioned above. The present invention also provides a method for producing compounds, as mentioned above, and compositions containing these compounds.
Need to check novelty before this filing date? Find Prior Art